NCT04964206 Neuraxial Labor Analgesia and Offspring Neurodevelopment
| NCT ID | NCT04964206 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dong-Xin Wang |
| Condition | Offspring, Adult |
| Study Type | OBSERVATIONAL |
| Enrollment | 5,580 participants |
| Start Date | 2022-10-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 5,580 participants in total. It began in 2022-10-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
How perinatal factors affect the long-term development of children has always been an issue of much concern. This study is designed to explore the potential impact of maternal neuraxial labor analgesia exposure on offspring neurodevelopment.
Eligibility Criteria
Inclusion Criteria: 1. Primiparae between 18 and 35 years of age with term single cephalic pregnancy; 2. Undergo regular prenatal examination in the study centers; 3. Preparing to deliver vaginally. Exclusion Criteria: 1. History of psychiatric diseases (indicate those that are diagnosed before or during pregnancy by psychiatrists); 2. History of diseases involving the hypothalamic-pituitary-adrenal axis; 3. Presence of contraindications to epidural analgesia, which includes: (1) History of infectious disease of the central nervous system (poliomyelitis, cerebrospinal meningitis, encephalitis, etc.); (2) History of spinal or intra-spinal disease (trauma or surgery of spinal column, intra-spinal canal mass, etc.); (3) Systemic infection (sepsis); (4) Skin or soft tissue infection at the site of epidural puncture; (5) Coagulopathy. 4. Presence of contraindications to vaginal delivery; 5. Other reasons that are considered unsuitable for study participation.
Contact & Investigator
Dong-Xin Wang, MD,PHD
PRINCIPAL INVESTIGATOR
Peking University First Hospital
Frequently Asked Questions
Who can join the NCT04964206 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 35 Years, studying Offspring, Adult. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04964206 currently recruiting?
Yes, NCT04964206 is actively recruiting participants. Contact the research team at wangdongxin@hotmail.com for enrollment information.
Where is the NCT04964206 trial being conducted?
This trial is being conducted at Beijing, China, Shenzhen, China.
Who is sponsoring the NCT04964206 clinical trial?
NCT04964206 is sponsored by Dong-Xin Wang. The principal investigator is Dong-Xin Wang, MD,PHD at Peking University First Hospital. The trial plans to enroll 5,580 participants.